Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Diwakar Davar"'
Autor:
Ananth Arjunan, Melissa Saul, Rahul Atul Parikh, Hong Wang, Tala Achkar, Diwakar Davar, Leonard Joseph Appleman, David M. Friedland
Publikováno v:
PLoS ONE, Vol 12, Iss 12, p e0190084 (2017)
PLoS ONE
PLoS ONE
Background High-dose interleukin-2 (HD IL-2) is used in the treatment of metastatic renal cell carcinoma (mRCC) and has an overall response rate (ORR) of 12–20% and a complete response rate (CR) of 8% in unselected populations with predominantly cl
Publikováno v:
Renal Cell Carcinoma ISBN: 9781627030618
Renal cell carcinoma (RCC) is a highly immunogenic tumor as evidenced by the occasional dramatic spontaneous remission seen even in advanced disease. Since the earliest days, immunotherapeutic approaches have been utilized in an attempt to replicate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8416f4a4c9030e9c78602146cd3ffccb
https://doi.org/10.1007/978-1-62703-062-5_16
https://doi.org/10.1007/978-1-62703-062-5_16
Autor:
John M. Kirkwood, Cindy Sander, Ahmad A. Tarhini, Hussein Tawbi, An Tran, Diwakar Davar, Melissa Saul, Kerry Trent
Publikováno v:
Journal of Clinical Oncology. 31:9075-9075
9075 Background: IL-2 is a T-cell growth factor tested in a variety of regimens for advanced melanoma (MEL) and renal cell carcinoma (RCC). High-dose IL-2 (600,000-720,000 IU/kg administered intravenously every 8 hours for up to 14 consecutive doses)